Appropriateness of psychotropic medication use in a cohort of adolescents with intellectual disability in Queensland, Australia

被引:6
|
作者
Song, Menghuan [1 ]
Ware, Robert S. [1 ,2 ]
Doan, Tan N. [3 ]
McPherson, Lyn [1 ,2 ]
Trollor, Julian N. [4 ]
Harley, David [1 ]
机构
[1] Univ Queensland, Mater Hosp, Queensland Ctr Intellectual & Dev Disabil, Mater Res Inst, Brisbane, Qld, Australia
[2] Griffith Univ, Menzies Hlth Inst Queensland, Nathan, Qld, Australia
[3] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Melbourne, Vic, Australia
[4] Univ New South Wales, Dept Dev Disabil Neuropsychiat, Fac Med, Sydney, NSW, Australia
来源
BJPSYCH OPEN | 2020年 / 6卷 / 06期
关键词
Psychotropic drugs; intellectual disability; off-label use; inappropriate prescribing; adolescent; ADULTS; DRUGS;
D O I
10.1192/bjo.2020.125
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Psychotropic medications are sometimes used off-label and inappropriately. This may cause harm to adolescents with intellectual disability. However, few studies have analysed off-label or inappropriate prescribing to this group. Aims To examine the appropriateness of psychotropic prescribing to adolescents with intellectual disability living in the community in south-east Queensland, Australia. Method Off-label medication use was determined based on whether the recorded medical condition treated was approved by the Australian Therapeutic Goods Administration. Clinical appropriateness of medication use was determined based on published guidelines and clinical opinion of two authors who specialise in developmental disability medicine (J.N.T. and D.H.). Results We followed 429 adolescents for a median of 4.2 years. A total of 107 participants (24.9%) were prescribed psychotropic medications on at least one occasion. Of these, 88 (82.2%) were prescribed their medication off-label or inappropriately at least once. Off-label or inappropriate use were most commonly associated with challenging behaviours. Conclusions Off-label or inappropriate use of psychotropic medications was common, especially for the management of challenging behaviours. Clinical decision-making accounts for individual patient factors and is made based on clinical experience as well as scientific evidence, whereas label indications are developed for regulatory purposes and, although appropriate at a population level, cannot encompass the foregoing considerations. Education for clinicians and other staff caring for people with intellectual disability, and a patient-centred approach to prescribing with involvement of families should encourage appropriate prescribing. The effect of the National Disability Insurance Scheme on the appropriateness of psychotropic medication prescribing should be investigated.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Psychotropic Medication Use in Children and Adolescents With Type 1 Diabetes
    Liu, Shengxin
    Lagerberg, Tyra
    Ludvigsson, Jonas F.
    Taylor, Mark J.
    Chang, Zheng
    D'Onofrio, Brian M.
    Larsson, Henrik
    Lichtenstein, Paul
    Gudbjornsdottir, Soffia
    Kuja-Halkola, Ralf
    Butwicka, Agnieszka
    JAMA NETWORK OPEN, 2023, 6 (10) : E2336621
  • [42] People with an unknown cause of intellectual disability use more psychotropic drugs
    Konijn, Chantal
    van der Heijden, Lisette
    Robroek, Pieter-Paul
    Verheul, Jiska
    de Waard, Yvette
    Oppewal, Alyt
    Mergler, Sandra
    JOURNAL OF APPLIED RESEARCH IN INTELLECTUAL DISABILITIES, 2021, 34 (05) : 1344 - 1344
  • [43] Psychotropic medication use for challenging behaviors in persons with intellectual disabilities: An overview
    Matson, Johnny L.
    Neal, Daniene
    RESEARCH IN DEVELOPMENTAL DISABILITIES, 2009, 30 (03) : 572 - 586
  • [44] Injury among adolescents with intellectual disability: A prospective cohort study
    White, David
    McPherson, Lyn
    Lennox, Nicholas
    Ware, Robert S.
    INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED, 2018, 49 (06): : 1091 - 1096
  • [45] Characteristics and the trajectory of psychotropic medication use in general and antipsychotics in particular among adults with an intellectual disability who exhibit aggressive behaviour
    Deb, S.
    Unwin, G.
    Deb, T.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2015, 59 (01) : 11 - 25
  • [46] Psychotropic medication for challenging behaviour in people with intellectual disability: Results of an online survey of family carers
    Sheehan, R.
    Kimona, K.
    Giles, A.
    Cooper, V.
    Hassiotis, A.
    EUROPEAN PSYCHIATRY, 2018, 48 : S240 - S240
  • [47] IMPROVING PSYCHOTROPIC MEDICATION PRESCRIBING IN PEOPLE WITH INTELLECTUAL DISABILITY IN UK PRIMARY CARE: AN EDUCATIONAL INTERVENTION
    Shankar, R.
    Wilcock, M.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2019, 63 (07) : 678 - 678
  • [48] Psychotropic medication use in a sample of frail, elderly inpatients in Sydney, Australia
    McInnes, E
    Mira, M
    Atkin, N
    Kennedy, P
    Cullen, J
    AUSTRALIAN JOURNAL ON AGEING, 1998, 17 (02): : 65 - 70
  • [49] Use of Medication among Young People with Intellectual Disability in Quebec
    Sirois, Caroline
    Gascon, Hubert
    Faubert, Mirella
    Gagnon, Marie-Eve
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2013, 22 : 515 - 515
  • [50] Use of psychotropic medication among adolescents and adults with autism spectrum disorders
    Fusar-Poli, L.
    Brondino, N.
    Rocchetti, M.
    Petrosino, B.
    Arillotta, D.
    Politi, P.
    Aguglia, E.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2019, 29 : S439 - S440